Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies
Fred Poordad, Norah A Terrault, Naim Alkhouri, Wei Tian, Lee F Allen, Mordechai Rabinovitz, Fred Poordad, Norah A Terrault, Naim Alkhouri, Wei Tian, Lee F Allen, Mordechai Rabinovitz
Abstract
Aims: Thrombocytopenia complicates the management of patients with chronic liver disease (CLD) undergoing invasive procedures with a bleeding risk. Until recently, prophylactic platelet transfusion was the only treatment option, but has significant safety and efficacy limitations. Phase 3 data demonstrated the superiority of avatrombopag to placebo in reducing platelet transfusions for bleeding, supporting its recent approval.
Methods: Integrated analyses of pooled data (N = 435) from two randomized, double-blind, placebo-controlled, phase 3 studies assessed the original efficacy endpoints. Additional analyses included subgroup analyses, alternate Baseline platelet count definitions, and another efficacy endpoint.
Results: Avatrombopag was superior to placebo in increasing patients not requiring a platelet transfusion or rescue procedure, those achieving a platelet count ≥50 × 109/L on Procedure Day, and the change in platelet counts from Baseline. The avatrombopag treatment effect was consistently positive across clinically important disease and Baseline clinical characteristic subgroups, and using alternate Baseline platelet count cohort definitions. Similarly, more avatrombopag-treated patients achieved ≥50 × 109/L platelets with an increase of ≥20 × 109/L from Baseline. The incidence and severity of adverse events were similar between avatrombopag and placebo. Further, safety data demonstrated a low risk for thromboembolic events and hepatotoxicity.
Conclusion: These integrated analyses confirmed the superiority of avatrombopag to placebo in reducing platelet transfusions or rescue procedures for bleeding in patients with thrombocytopenia and CLD scheduled to undergo an invasive procedure, and its tolerable safety profile. Importantly, these data warrant reconsideration of clinical decision making regarding the need to treat thrombocytopenia in patients with CLD. This trial was registered with NCT01972529 and NCT01976104.
Conflict of interest statement
Fred Poordad, Norah A. Terrault, Naim Alkhouri, and Mordechai Rabinovitz have had consulting agreements in the past with Dova Pharmaceuticals Inc. Wei Tian and Lee F. Allen are employed by Dova Pharmaceuticals Inc.
Copyright © 2020 Fred Poordad et al.
Figures
References
- Maan R., Knegt R. J., Veldt B. J. Management of thrombocytopenia in chronic liver disease: focus on pharmacotherapeutic strategies. Drugs. 2015;75(17):1981–1992. doi: 10.1007/s40265-015-0480-0.
- Giannini E. G., Greco A., Marenco S., Andorno E., Valente U., Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clinical Gastroenterology and Hepatology. 2010;8(10):899–902. doi: 10.1016/j.cgh.2010.06.018.
- Mitchell O., Felman D. M., Diakow M., Sigal S. H. The pathophysiology of thrombocytopenia in chronic liver disease. Hepatic Medicine: Evidence and Research. 2016;8:39–50. doi: 10.2147/hmer.s74612.
- Afdhal N., McHutchison J., Brown R., et al. Thrombocytopenia associated with chronic liver disease. Journal of Hepatology. 2008;48(6):1000–1007. doi: 10.1016/j.jhep.2008.03.009.
- Qureshi K., Patel S., Meillier A. The use of thrombopoietin receptor agonists for correction of thrombocytopenia prior to elective procedures in chronic liver diseases: review of current evidence. International Journal of Hepatology. 2016;2016:1–9. doi: 10.1155/2016/1802932.
- Poordad F. Review article: thrombocytopenia in chronic liver disease. Alimentary Pharmacology & Therapeutics. 2007;26:5–11. doi: 10.1111/j.1365-2036.2007.03510.x.
- Rockey D. C., Caldwell S. H., Goodman Z. D., Nelson R. C., Smith A. D., American Association for the Study of Liver Diseases Liver biopsy. Hepatology. 2009;49(3):1017–1044. doi: 10.1002/hep.22742.
- Patel I. J., Davidson J. C., Nikolic B., et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. Journal of Vascular and Interventional Radiology. 2012;23(6):727–736. doi: 10.1016/j.jvir.2012.02.012.
- Schiffer C. A., Bohlke K., Delaney M., et al. Platelet transfusion for patients with cancer: american society of clinical oncology clinical practice guideline update. Journal of Clinical Oncology. 2018;36(3):283–299. doi: 10.1200/JCO.2017.76.1734.
- Slichter S. J. Evidence-based platelet transfusion guidelines. Hematology American Society of Hematology Education Program. 2007;(1):172–178. doi: 10.1182/asheducation-2007.1.172.
- Szczepiorkowski Z. M., Dunbar N. M. Transfusion guidelines: when to transfuse. Hematology American Society of Hematology Education Program. 2013;2013(1):638–644. doi: 10.1182/asheducation-2013.1.638.
- Estcourt L. J., Birchall J., Allard S., et al. Guidelines for the use of platelet transfusions. British Journal of Haematology. 2017;176(3):365–394. doi: 10.1111/bjh.14423.
- ASGE Standards of Practice Committee, Maple J. T., Ben-Menachem T., et al. The role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointestinal Endoscopy. 2010;71(1):1–9. doi: 10.1016/j.gie.2009.09.041.
- Blumberg N., Heal J. M., Phillips G. L. Platelet transfusions: trigger, dose, benefits, and risks. F1000 Medicine Reports. 2010 doi: 10.3410/M2-5.
- Stanworth S. J., Navarrete C., Estcourt L., Marsh J. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. British Journal of Haematology. 2015;171(3):297–305. doi: 10.1111/bjh.13597.
- Meehan K. R., Matias C. O., Rathore S. S., et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. American Journal of Hematology. 2000;64(4):251–256. doi: 10.1002/1096-8652(200008)64:4<251:aid-ajh3>;2-n.
- Shirley M. Avatrombopag: first global approval. Drugs. 2018;78(11):1163–1168. doi: 10.1007/s40265-018-0949-8.
- Doptlet [package insert] Durham, NC: Dova Pharmaceuticals, Inc; 2018.
- Mulpleta [package insert] Florham Park, NJ: Shionogi, Inc.; 2018.
- Kim E. S. Lusutrombopag: first global approval. Drugs. 2016;76(1):155–158. doi: 10.1007/s40265-015-0525-4.
- Fukushima-Shintani M., Suzuki K., Iwatsuki Y., et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. European Journal of Haematology. 2009;82(4):247–254. doi: 10.1111/j.1600-0609.2008.01198.x.
- Terrault N., Chen Y. C., Izumi N., et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):705–718. doi: 10.1053/j.gastro.2018.05.025.
- Terrault N. A., Hassanein T., Howell C. D., et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. Journal of Hepatology. 2014;61(6):1253–1259. doi: 10.1016/j.jhep.2014.07.007.
- Afdhal N. H., Giannini E. G., Tayyab G., et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. New England Journal of Medicine. 2012;367(8):716–724. doi: 10.1056/nejmoa1110709.
- Afdhal N. H. Lusutrombopag for treatment of thrombocytopenia in patients with chronic liver disease who are undergoing non-emergency invasive procedures: results from an international phase 3, randomized, double-blind, placebo-controlled study (L-PLUS 2) Hepatology. 2017;66(6):p. 1254A.
Source: PubMed